Selegiline HCL Tablets USP 5mg — Class III drug recall D-1479-2016
Terminated recall by Stason Pharmaceuticals, Inc., reported 2016-09-14, distributed in NC. Stason Pharmaceuticals is recalling Selegiline HCl tablets, USP 5mg 60 count bottle due to an out of specifica
| Recall number | D-1479-2016 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Stason Pharmaceuticals, Inc., Irvine, CA, United States |
| Recall initiated | 2016-08-23 |
| Classified | 2016-09-02 |
| Reported by FDA | 2016-09-14 |
| Terminated | 2017-10-23 |
| Distributed | NC |
| Quantity | 17,013 units |
| Reason classes | specification failure |
| NDC | 51862-0146-06 |
| Lot numbers | 14F030, 14F031, 14F032, 15G022 |
| Expiration dates | 2017-06-20, 2018-07-20 |
Product
Selegiline HCL Tablets USP 5mg, 60- count bottles, Rx only, Manufactured by: Stason Pharmaceuticals, Inc. Irvine, CA 92618 Distributed by: Libertas Pharma, Inc. Montgomery, AL 36117. NDC 51862-146-06
Reason for recall
Stason Pharmaceuticals is recalling Selegiline HCl tablets, USP 5mg 60 count bottle due to an out of specification result for dissolution of stability samples.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1479-2016. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.